You are here: Industry Insights > Remdesivir

News List

Final Report Confirms Remdesivir Benefits for COVID-19 americanpharmaceuticalreview
October 28, 2020
Remdesivir is an antiviral medication that targets a range of viruses. It was originally developed over a decade ago to treat hepatitis C and a cold-like virus called respiratory syncytial virus (RSV). Remdesivir wasn’t an effective treatment for ...
Mexico may not follow FDA and approve remdesivir for COVID-19 expresspharma
October 26, 2020
WHO Solidarity drug trial last week concluded remdesivir has little or no impact on a patient’s chances of surviving COVID-19.
Remdesivir price curbs in India make COVID-19 treatment more affordable: GlobalData expresspharma
October 19, 2020
Maharashtra has fixed the price of remdesivir at Rs 2,360, 16 per cent more economical than the cheapest brand Remdac at Rs 2,800 by Zydus Cadila and 56 per cent more economical than Covifor at Rs 5,400 by Hetero Labs.
Remdesivir alone or in combination with other drugs considered most promising drug for COVID-19: Poll pharmaceutical-technology
October 16, 2020
The COVID-19 infection caused by the SARS-CoV-2 currently does not have any treatment although several existing approved drugs are being used to treat the disease symptoms.
Lilly, Incyte Release Information on Baricitinib, Remdesivir Combination for COVID-19 americanpharmaceuticalreview
October 15, 2020
Eli Lilly and Company and Incyte are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir.
Hovione to Support Manufacture of Remdesivir for COVID-19 contractpharma
September 24, 2020
To meet Captisol demand associated with Remdesivir, Hovione will be producing per month the quantity it usually produces in one year.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury (remdesivir) for the Treatment of COVID-19 drugs.com
September 23, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury (remdesivir)...
Baricitinib, Remdesivir Trial Reduces Recovery Time in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 21, 2020
Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Dr Reddy’s Laboratories launches Redyx (remdesivir) in India expresspharma
September 18, 2020
It is available in the strength of 100 mg vial.
Baricitinib in combination with remdesivir reduces recovery time in hospitalised COVID-19 patients: Study expresspharma
September 16, 2020
Data from the Adaptive COVID-19 Treatment Trial (ACTT-2) revealed an approximately one-day reduction in median recovery time for the overall patient population.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page